Lexaria Announces $3.6 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
February 15, 2024
Consumer Packaged Goods
-
-
Better Choice Acquires Aimia Pet Healthco to Enter the GLP1 Pet Market
February 9, 2024
-
Inomin Expands Beaver-Lynx Critical Minerals Project
January 19, 2024
-
Lexaria Unveils Extensive Planned 2024 GLP-1 Study Program
January 16, 2024
-
Lexaria Bioscience Corp. (NASDAQ: LEXX) Improves Delivery, Efficacy of GLP-1 Agonists Through Proprietary Drug-Delivery Platform
January 9, 2024
-
Lexaria’s Patented Technology Improved the Oral Performance of the Rybelsus-Branded GLP-1 drug Semaglutide
January 4, 2024
-
Bit Origin Ltd Secures $6.74 Million Investment to Build a New Crypto Mining Data Center in the U.S.
December 11, 2023
-
Lexaria’s Technology Lowers Blood Glucose More Effectively than Rybelsus-Branded GLP-1 drug Semaglutide Alone in Human Pilot Study
November 28, 2023
-
Lexaria’s Technology Improves the Oral Performance of the Rybelsus-Branded GLP-1 drug Semaglutide in Human Pilot Study
November 27, 2023
-
Blue Star Foods Provides Shareholder Update
November 27, 2023
-
Bit Origin Ltd Announces New Financing and Provides Business Plan Update
November 22, 2023
-
Lexaria Bioscience Corp. (NASDAQ: LEXX) Receives Two New Canadian Patents Amid Continued Efforts to Safeguard the Applicability of Its DehydraTECH(TM) Technology in Multiple Jurisdictions and Sectors
October 26, 2023
-
Nightfood Schedules Investor Conference Call for Wednesday, November 1, 2023 at 4:30 PM Eastern
October 16, 2023
-
Lexaria Enters New Global Exclusive Collaboration and License Agreement with SulfoSyn
October 13, 2023
-
Lexaria Granted Two New Patents in Canada
October 12, 2023
-
Lexaria Announces Pricing of $1.6 Million Registered Direct Offering
September 29, 2023